부산대학교 도서관

The management of warfarin dose is challenging due to its narrow therapeutic index and large interpatient variability. CYP2C9, VKORC1 variants along with known non-genetic factors accounts for ~50% of warfarin dose variability. Additionally a CYP4F2 variant has shown to influence warfarin dose and therefore due to absence of data from the western India, the present study was aimed to determine the effect of CYP4F2 variant in warfarin dose management. Genomic DNA was extracted from 80 patients undergoing warfarin therapy and 30 healthy controls. Their mean daily warfarin dose, international normalized ratio (INR) and demographics were recorded and genotyping of CYP4F2 variant was performed by allele-specific PCR method and validated by sanger sequencing. The CYP4F2 rs2108622 minor allele frequency in the patient and controls were found to be 40 and 42% respectively, which was observed to be higher than that reported in the Caucasian population (30%). The mean warfarin dose did not show significance between the CYP4F2 genotypes. However, on subgroup analysis, it was revealed that the variant CYP4F2 allele was significantly (p < 0.05) associated in patients with supra and sub-therapeutic INR as compared to patients with therapeutic INR. The present study, a first from Western India shows a promising association between CYP4F2 rs2108622 variant and INR. Further validation on larger Indian cohort will be required in order to establish the true clinical utility of CYP4F2 variant in management of patients on Warfarin therapy. KEYWORDS: Warfarin, INR, CYP4F2, Western India.
P197 Minal U. Paradkar (1), Swarup A. V. Shah (1), Sripriya Natarajan (1), Chandrashekar K. Ponde (2), Rajesh M. Rajani (2), Farah Jijina (3), Roopkumar Gursahani (4), Tester F. Ashavaid [...]